New breast cancer drug approved

New breast cancer drug approved




According to information the American Cancer Society, Breast cancer begins when breast cells begin to grow out of control. Breast cancer cells usually form a tumor that can often be seen on an x-ray or felt as a mass or lump.

Breast cancer occurs almost exclusively in women, but men can get it too. Among the tools that Mayo Clinic considered as preventive are self-examination, frequent appointments with specialists in case there is a family history with cases of this type of cancer and that the people you breastfeed (especially women) know their bodies.

Today, August 5, 2022, the Astrazeneca laboratory and Daiichi Sankyo received approval from the United States Food and Drug Administration (FDA) that expands the use of its Enhertu therapy for patients with breast cancer.

Enhertu is a drug specifically targeted at patients with so-called low HER2 breast cancer. The FDA approved the drug based on data from a late-stage study involving more than 550 patients with HER2-low breast cancer.

The data presented showed that Enhertu prolongs survival by an additional 6.4 months in patients with hormone-sensitive tumours.

Read:  Is it possible to reduce scars?

Related Notes: